Bevacizumab was also found to trigger FcγR-mediated responses and to inhibit another immunoregulatory biomolecule beyond VEGF, which points out to the diversity of actions of this antibody in the tumor immune landscape. The gene discussed is FCGR2A; the disease is neoplasm.